Literature DB >> 10653067

Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic.

A K Malik1, A J Taylor.   

Abstract

BACKGROUND: Subjects in clinical trials may benefit from the increased attention and specific focus of the trial, thereby limiting the external validity of clinical trial results to clinical practice. Our study evaluated adherence to guidelines for intensity of anticoagulation in a large, university-based warfarin clinic to assess the generalizability of randomized clinical trials of warfarin efficacy to clinical practice.
METHODS: We reviewed anticoagulation clinic records of 480 patients observed for up to 2 years to determine the amount of time anticoagulation was within the recommended therapeutic range.
RESULTS: The most common indication for warfarin use was atrial arrhythmia (51.5%). Overall, anticoagulation was within the intended international normalized ratio (INR) target range on 57.8% of treatment days. Nontherapeutic treatment days were due more commonly to subtherapeutic INR values (27.6+/-25.7%) than supratherapeutic INR values (14.9+/-17.0%). This pattern was seen across all warfarin indications.
CONCLUSION: These data are comparable to those reported from large randomized trials and thus support the generalizability of clinical trials of long-term warfarin anticoagulation to clinical practice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10653067

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  6 in total

Review 1.  A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation.

Authors:  D A Fitzmaurice; P Kesteven; K M Gee; E T Murray; R McManus
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

Review 2.  New approaches to anticoagulation in atrial fibrillation.

Authors:  Palle Petersen
Journal:  Curr Cardiol Rep       Date:  2004-09       Impact factor: 2.931

3.  Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry.

Authors:  Alvaro Alonso; Joel M Gore; Hamza H Awad; Ann L Quill; Gilles Montalescot; Frans van de Werf; Dietrich C Gulba; Keith A A Fox; Kim A Eagle; Christopher B Granger; Allison Wyman; Ph Gabriel Steg
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09

Review 4.  Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.

Authors:  Elizabeth S Mearns; Jessica Hawthorne; Ju-Sung Song; Craig I Coleman
Journal:  BMJ Open       Date:  2014-06-20       Impact factor: 2.692

5.  Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.

Authors:  Elizabeth S Mearns; C Michael White; Christine G Kohn; Jessica Hawthorne; Ju-Sung Song; Joy Meng; Jeff R Schein; Monika K Raut; Craig I Coleman
Journal:  Thromb J       Date:  2014-06-24

6.  Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data.

Authors:  Taru Hallinen; Erkki J Soini; Christian Asseburg; Pekka Kuosmanen; Ari Laakkonen
Journal:  BMJ Open       Date:  2014-02-27       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.